cancers

IMPACT FACTOR 5.2

Indexed in: PubMed

CITESCORE 7.4

an Open Access Journal by MDPI

Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion

Guest Editor:

Dr. Huey-Jen Lin
Department of Medical and Molecular Sciences, College of Health Sciences, University of Delaware, Newark, DE 19716, USA

Deadline for manuscript submissions:
closed (31 May 2023)

Message from the Guest Editor

It was widely recognized that the complex interplay between immunity and cancer determines whether cancer cells will survive or be destroyed. The battle between tumoricidal and tumor promoting activity relies on the extent to which the antitumor immune response is exerted. In general, immune evasive mechanisms adapted by cancers encompass downregulation of antigen presentations or recognition, lack of immune effector cells, obstruction of antitumor immune cell maturation, accumulation of immunosuppressive cells, production of inhibitory cytokines, chemokines or ligands/receptors, establishment of a hypoxic tumor microenvironment, development of cancer-promoting metabolisms, and upregulation of immune checkpoint modulators. As such, restoring or stimulating tumoricidal effects, in conjunction with surgical resection, as well as chemo- or radiation-mediated, hormone-based, kinase-targeted, DNA repair-disrupted, small molecule inhibitor-mediated, signal transduction pathway-modified, aberrant epigenome-reverted, and cytokine-involved treatments, may ignite promising therapeutic regiments to eradicate fatal cancers.

cancers

IMPACT FACTOR 5.2 | Indexed in: PubMed | CITESCORE 7.4

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
𝕏@Cancers_MDPI